"Lamivudine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
| Descriptor ID |
D019259
|
| MeSH Number(s) |
D03.383.742.680.245.500.950.500 D13.570.230.329.950.500 D13.570.230.500.925.500 D13.570.685.245.500.950.500
|
| Concept/Terms |
Lamivudine- Lamivudine
- 3TC
- 2',3'-Dideoxy-3'-thiacytidine
- 2',3' Dideoxy 3' thiacytidine
|
Below are MeSH descriptors whose meaning is more general than "Lamivudine".
Below are MeSH descriptors whose meaning is more specific than "Lamivudine".
This graph shows the total number of publications written about "Lamivudine" by people in this website by year, and whether "Lamivudine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 1 | 2 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 3 | 2 | 5 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 4 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lamivudine" by people in Profiles.
-
Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426.
-
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15?years. Contemp Clin Trials. 2024 Jul; 142:107540.
-
Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024 Jul; 25(7):826-839.
-
Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
-
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. Lancet HIV. 2023 08; 10(8):e506-e517.
-
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495.
-
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. Antivir Ther. 2023 02; 28(2):13596535231168480.
-
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Pediatr Infect Dis J. 2022 10 01; 41(10):827-834.
-
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS. 2021 04 01; 35(5):759-767.
-
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. Sci Rep. 2021 02 04; 11(1):3173.